<DOC>
	<DOCNO>NCT00405808</DOCNO>
	<brief_summary>Primary objective : To determine effect Rimonabant 20mg co-primary endpoint include Fasting Plasma Glucose ( FPG ) , HDL-Cholesterol ( HDL-C ) triglyceride ( TG ) level period 12 month prescribe mild hypocaloric diet abdominally obese patient impaired fasting blood glucose without associated comorbidities . Main Secondary objective : To determine effect 12 month Rimonabant treatment versus placebo change waist circumference ( WC ) , body weight , glycemic parameter lipid parameter . To assess safety 12 month Rimonabant treatment versus placebo patient .</brief_summary>
	<brief_title>Rimonabant Abdominally Obese Patients With Impaired Fasting Blood Glucose</brief_title>
	<detailed_description />
	<mesh_term>Rimonabant</mesh_term>
	<criteria>BMI ≥ 30Kg/m² , &gt; 27kg/m² associate risk factor ( ) dyslipidemia , &lt; 40kg/m² , Waist Circumference &gt; 88 cm woman ; &gt; 102 cm men , Confirmed ( least 2 measurement ) impair Fasting Plasma Glucose ( FPG ≥ 100 mg/dl ( 5.6 mmol/L ) &lt; 126 mg/dl ( 7.0 mmol/L ) non diabetic patient , LDL cholesterol 155 mg/dl ( 4.00 mmol/L ) include patient stable dose statin therapy least 8 week prior screen , Current treatment statin and/or ezetimibe and/or antihypertensive therapy must fix stable dose least 8 week prior screen visit , Patients , willing opinion Investigator safely assume remain stable fixed dos antihypertensive , and/or statin and/or ezetimibe without add additional medication change current treatment duration trial . Pregnant breastfeed woman , woman plan become pregnant breastfeed ( excluded pregnancy test ) , Absence medically approve contraceptive method female childbearing potential , History lowcalorie diet within 3 month prior screen visit ( low 1200 Kcal/day ) , Weight change &gt; 5 kg within 3 month prior screen visit , History surgical procedure weight loss ( e.g. , stomach stapling , bypass ) , History bulimia anorexia nervosa per DSMIV criterion , Presence clinically significant endocrine disease accord investigator , particular know abnormal TSH free T4 blood level ( Patients treat thyroid replacement therapy must fix stable dose least 3 month prior screen must euthyroïd status ) , Established type 1 2 diabetes treat , least 2 measure fast blood glucose ≥ 126 mg/dl /L , Triglyceride level &gt; 400 mg/dL ( 4.52 mmol ) , Systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 100 mmHg screen visit , Known severe renal dysfunction ( creatinine clearance &lt; 30 ml/min ) nephrotic syndrome urinalysis ( perform screen dipstick ) show 2+ protein , Known severe hepatic impairment AST and/or ALT &gt; 3 time upper limit normal screening , Presence condition ( medical , include clinically significant abnormal laboratory test , psychological , social geographical ) actual anticipate investigator feel would compromise patient 's safety limit his/her successful participation study . In particular : Cardiac abnormality : cardiac failure status NYHA III IV , relevant acute abnormal find see ECG screen within 6 month screen , Any current malignancy cancer within past five year ( except adequately treat basal cell skin cancer cervix carcinoma situ ) , Significant haematology abnormality ( haemoglobin &lt; 100 g/L and/or neutrophil &lt; 1.5 G/L and/or platelet &lt; 100 G/L ) , Acute psychiatric disorder mental condition could interfere patient 's compliance safe participation study , Patient treat epilepsy , Ongoing major depressive illness , Uncontrolled psychiatric illness , History alcohol substance abuse , Hypersensitivity /intolerance active substance excipients lactose , Administration investigational treatment ( drug device ) within 30 day prior screen , Previous participation Rimonabant study previous administration Rimonabant , Administration follow within 3 month prior screen visit : 1 . Anti obesity drug ( eg , sibutramine , orlistat ) , 2 . Other drug weight reduction ( phentermine , amphetamine ) , 3 . Herbal preparation weight reduction , 4 . Nicotinic acid , fibrates bile acid sequestrants , 5 . Prolonged use ( one week ) systemic corticosteroid , neuroleptic . 6 . Omega3 fatty acid approve medication Ongoing antidepressive treatment ( include bupropion ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>